source
- FDA sends warning to Alar over misleading claims about investigational depression drugThe U.S. Food and Drug Administration’s Office of Prescription Drug Promotion sent an untitled warning letter to Alar Pharmaceuticals. The agency says Alar’s promotional materials for ALA-3000, an…
- FDA considers two new executive posts and approves first-of-its-kind early drug and ketone‑glucose wearableThe Health and Human Services department is reportedly evaluating the creation of two additional senior positions within the FDA, a step that could increase agency oversight. In recent approvals,…